Personalis - PSNL Operating profit EBITDA
Personalis, Inc. (PSNL) generates revenue from high-precision genetic tests for personalized therapy and pharmaceutical development support. Business scalability is driven by DNA software analysis, which reduces research costs. Its status as a scientific innovator is confirmed by the trust of leading oncology centers. The EBITDA financial metric reflects the actual volume of cash inflows from operations, with the indicator remaining at 0.00.
Personalis (PSNL) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
- earnings and market ratios statistics:
PSNL - Company Net Income|Net Profit Forecast Personalis, Inc.|PSNL - P/E Multiple|Forward P/E Multiple personalis.com|PSNL - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Personalis|PSNL - Operating profit EBITDA|Net earnings per share for the last four quarters Personalis|PSNL - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months personalis.com|PSNL - Net earnings per share growth this year|Expected earnings per share trend next year Personalis, Inc.
Analysis of all company metrics:Personalis Genomics
The development of NeXT Personal NGS testing by Personalis, Inc. (PSNL) requires significant R&D capital expenditures and partnerships with big pharma. This indicator measures the actual inflow of liquidity from operating activities, excluding the accounting lags of quarterly reporting. This allows investors to promptly detect the depletion of cash flows or their abnormal growth. Analysis of absolute operating profit reveals the real viability of the business model. The trend in absolute operating profit serves as a leading indicator of the company's financial health.
Competitors of Personalis, Inc. (PSNL)
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Profit before payment of interest, taxes and amortization Erasca, Inc. (ERAS)|DCTH: Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA YMAB (Y-mAbs Therapeutics, Inc.)|Aura Biosciences Inc (AURA) - Profit before interest, taxes and amortization|CADL - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization ARAY (Accuray, Inc.)|sellaslifesciences.com (SLS) - Profit before payment of interest, taxes and amortization|ACTU - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Citius Oncology|Profit before interest, taxes and amortization TuHURA HURA|Profit before payment of interest, taxes and amortization Protara (TARA)|Fate Pharma - Operating profit before amortization|Operating profit EBITDA WHWK (Aadi Bioscience)|Operating profit EBITDA TScan Therapeutics Inc TCRX|CSBR - Profit before payment of interest, taxes and amortization|XBIT: Profit before payment of interest, taxes and amortization|CVM: Operating profit EBITDA|OSTX - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Radiopharm Theranostics|Artiva (ARTV) - Operating income before deduction of amortization|Operating profit before deduction of amortization ANL (Adlai Nortye Ltd.)|VERU (Veru Inc) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA TPST (Tempest Tx)|Operating income before deduction of amortization Xilio Therapeutics Inc (XLO)|RENB - Profit before payment of interest, taxes and amortization|MURA (Mural Oncology plc) - Operating profit before amortization|KAPA: Operating profit EBITDA|Operating profit before deduction of amortization OnKure Therapeutics|Operating profit before deduction of amortization GDTC|Curis Corp (CRIS) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Apollomics, Inc. (APLM)|THAR: Profit before deduction of interest, taxes, depreciation and amortization|Profit before payment of interest, taxes and amortization Advanced Biomed ADVB|Operating income before deduction of amortization Genprex Inc. (GNPX)|CLDI - Profit before payment of interest, taxes and amortization|SBFM (sunshinebiopharma.com) - Operating profit before amortization|xeneticbio.com (XBIO) - Profit before payment of interest, taxes and amortization|SLRX (salariuspharma.com) - Profit before payment of interest, taxes and amortization|PPBT (Purple Biotech Ltd.) - Operating profit EBITDA|Operating profit before deduction of amortization AON (AONC)|Operating profit EBITDA BGNE|Operating profit EBITDA Checkpoint Therapeutics Inc (CKPT)|Profit before payment of interest, taxes and amortization Elevation Oncology ELEV|ICAD: Operating profit before amortization|Ikena - Operating profit EBITDA|Notable Labs Ltd (NTBL) - Operating profit before deduction of amortization|VIRX: Operating profit EBITDA|Profit before interest, taxes and amortization MorphoSys Corporation (MOR)|Profit before payment of interest, taxes and amortization NAYA Biosciences|AAPGV: Income before deduction of interest, taxes and amortization
